PMID- 15824174
OWN - NLM
STAT- MEDLINE
DCOM- 20050628
LR  - 20201222
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 14
IP  - 4
DP  - 2005 Apr
TI  - Multiplexed immunobead-based cytokine profiling for early detection of ovarian 
      cancer.
PG  - 981-7
AB  - Early detection of ovarian cancer might improve clinical outcome. Some studies 
      have shown the role of cytokines as a new group of tumor markers for ovarian 
      cancer. We hypothesized that a panel comprised of multiple cytokines, which 
      individually may not show strong correlation with the disease, might provide 
      higher diagnostic power. To evaluate the diagnostic utility of cytokine panel, we 
      used a novel multianalyte LabMAP profiling technology that allows simultaneous 
      measurement of multiple markers. Concentrations of 24 cytokines 
      (cytokines/chemokines, growth, and angiogenic factors) in combination with cancer 
      antigen-125 (CA-125), were measured in sera of 44 patients with early-stage 
      ovarian cancer, 45 healthy women, and 37 patients with benign pelvic tumors. Six 
      markers, i.e., interleukin (IL)-6, IL-8, epidermal growth factor (EGF), vascular 
      endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), and 
      CA-125, showed significant differences in serum concentrations between ovarian 
      cancer and control groups. Out of this group, IL-6, IL-8, VEGF, EGF, and CA-125, 
      were used in a classification tree analysis that resulted in 84% sensitivity at 
      95% specificity. The receiver operator characteristic curve created using the 
      combination of markers produced sensitivities between 90% and 100% in the area of 
      80% to 90% specificity, whereas the receiver operator characteristic curve for 
      CA-125 alone resulted in sensitivities of 70% to 80%. The classification tree 
      analysis for discrimination of benign condition from ovarian cancer used CA-125, 
      granulocyte colony-stimulating factor (G-CSF), IL-6, EGF, and VEGF resulting in 
      86.5% sensitivity and 93.0% specificity. The presented data show that 
      simultaneous testing of a panel of serum cytokines and CA-125 using LabMAP 
      technology may present a promising approach for ovarian cancer detection.
FAU - Gorelik, Elieser
AU  - Gorelik E
AD  - Department of Pathology and Immunology, University of Pittsburg School of 
      Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, 
      USA.
FAU - Landsittel, Douglas P
AU  - Landsittel DP
FAU - Marrangoni, Adele M
AU  - Marrangoni AM
FAU - Modugno, Francesmary
AU  - Modugno F
FAU - Velikokhatnaya, Lyudmila
AU  - Velikokhatnaya L
FAU - Winans, Matthew T
AU  - Winans MT
FAU - Bigbee, William L
AU  - Bigbee WL
FAU - Herberman, Ronald B
AU  - Herberman RB
FAU - Lokshin, Anna E
AU  - Lokshin AE
LA  - eng
GR  - P30 CA047904-17/CA/NCI NIH HHS/United States
GR  - R01 CA098642-02/CA/NCI NIH HHS/United States
GR  - R01 CA098642-01A1/CA/NCI NIH HHS/United States
GR  - R03 CA102888-01/CA/NCI NIH HHS/United States
GR  - U01 CA084968-06/CA/NCI NIH HHS/United States
GR  - R03 CA102888/CA/NCI NIH HHS/United States
GR  - R03 CA102888-02/CA/NCI NIH HHS/United States
GR  - 1R01 CA098642-01A1/CA/NCI NIH HHS/United States
GR  - U01 CA084968-05/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-125 Antigen)
RN  - 0 (Cytokines)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - CA-125 Antigen/*blood
MH  - Case-Control Studies
MH  - Cytokines/*blood
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Ovarian Neoplasms/blood/*diagnosis/pathology
MH  - Predictive Value of Tests
MH  - ROC Curve
EDAT- 2005/04/13 09:00
MHDA- 2005/06/29 09:00
CRDT- 2005/04/13 09:00
PHST- 2005/04/13 09:00 [pubmed]
PHST- 2005/06/29 09:00 [medline]
PHST- 2005/04/13 09:00 [entrez]
AID - 14/4/981 [pii]
AID - 10.1158/1055-9965.EPI-04-0404 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7. doi: 
      10.1158/1055-9965.EPI-04-0404.